Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 3/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.42 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630703 | 1.00 | SLC7A5 (0.57) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL594571 | 1.00 | SLC7A5 (0.57) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL27704336 | 0.98 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL4422991 | 0.98 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL7687022 | 0.98 | SLC7A5 (0.56) | SLC7A5TAAR1SLC6A2ESR1ESR2 | |
| SCHEMBL7395431 | 0.88 | ACACB (0.44) | SLC7A5ESR1ESR2CTSSCTSK | |
| SCHEMBL6666822 | 0.87 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL3203564 | 0.87 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL17978113 | 0.87 | SLC7A5 (0.45) | SLC7A5 | |
| SCHEMBL17978114 | 0.87 | SLC7A5 (0.45) | SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240101642-A1 | SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS | DUKE UNIVERSITY | 2024-03-28 | — | — | US | disclosed |
| US-11879038-B2 | Supramolecular gel supported on open-cell polymer foam | UNIVERSITE DE STRASBOURG (FR) | 2024-01-23 | — | — | US | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| US-11866482-B2 | System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators | DUKE UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220315710-A1 | SUPRAMOLECULAR GEL SUPPORTED ON OPEN-CELL POLYMER FOAM | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2022-10-06 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-100528842-C | Diphenylazetidinone derivatives for the treatment of disorders of lipid metabolism | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| CN-101058556-A | Diphenylacetidinon derivatives for treatment of disordered lipid metabolism, method of production thereof(variants), pharmaceutical composition | ASTRAZENECA AB (SE) | 2007-10-24 | — | — | CN | disclosed |
| CN-1665783-A | Diphenylazetidinone derivatives for the treatment of disorders of lipid metabolism | ASTRAZENECA AB (SE) | 2005-09-07 | — | — | CN | disclosed |
| CN-1204889-C | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 2005-06-08 | — | — | CN | disclosed |
| EP-0697408-B1 | 1 substituted-phenyl-oxazolidene-2-one derivatives and their use as adhesion-receptor antagonists | MERCK PATENT GMBH (DE) | 2002-01-23 | — | — | EP | disclosed |
| CN-1125575-A | Adhesion receptor antagonists | MERCK PATENT GMBH (DE) | 1996-07-03 | — | — | CN | disclosed |
| EP-0697408-A1 | 1 substituted-phenyl-oxazolidene-2-one derivatives and their use as adhesion-receptor antagonists | MERCK PATENT GmbH (DE) | 1996-02-21 | — | — | EP | disclosed |
| US-4572894-A | USING AMINOACYL-TRNA SYNTHETASE AS CONDENSING AGENT | Imahori, Kazutomo (JP) | 1986-02-25 | — | — | US | disclosed |
| EP-0086053-B1 | PROCESS FOR SYNTHESIZING PEPTIDES OR PEPTIDE DERIVATIVES | Imahori, Kazutomo (JP) | 1986-01-02 | — | — | EP | disclosed |
| EP-0086053-A1 | Process for synthesizing peptides or peptide derivatives | Imahori, Kazutomo (JP) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101642-A1 | SYSTEM AND METHOD FOR HOMOGENOUS GPCR PHOSPHORYLATION AND IDENTIFICATION OF BETA-2 ADRENERGIC RECEPTOR POSITIVE ALLOSTERIC MODULATORS | ADRB2, ARRB1, ADRB1 | SLC7A5 4655/4885TAAR1 568/4885SLC6A2 1616/4885 |
| US-11866482-B2 | System and method for homogenous GPCR phosphorylation and identification of beta-2 adrenergic receptor positive allosteric modulators | ADRB2, ARRB1, ADRB1 | SLC7A5 4655/4885TAAR1 568/4885SLC6A2 1616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.